

Lab on a Chip

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

Article type: Full paper

Non-contact acoustic capture of microparticles from small plasma volumes

Mikael Evander^a, Olof Gidlöf^b, Björn Olde^b, David Erlinge^b and Thomas Laurell^a^a Department of Biomedical Engineering, Lund University, Box 118, 221 00 Lund, Sweden^b Department of Cardiology, Clinical Sciences, Lund University, Box 118, 221 00 Lund, Sweden**Abstract**

Microparticles (MP) are small (100-1000 nm) membrane vesicles shed by cells as a response to activation, stress or apoptosis. Platelet-derived MP (PMP) has been shown to reflect the pathophysiological processes of a range of cardiovascular diseases and there is a potential clinical value in using PMPs as biomarkers, as well as a need to better understand the biology of these vesicles. The current method for isolating MP depends on differential centrifugation steps, which require relatively large sample volumes and have been shown to compromise the integrity and composition of the MP population. We present a novel method for rapid, non-contact capture of PMP in minute sample volumes based on a microscale acoustic standing wave technology. Capture of PMPs from plasma is shown by scanning electron microscope and flow cytometry. Furthermore, the system is characterized with regards to plasma sample concentration and flow rate. Finally, the technique is compared to a standard differential centrifugation protocol using samples from both healthy controls and ST-elevation myocardial infarction (STEMI) patient samples. The acoustic system is shown to offer a quick and automated setup for extracting microparticles from small sample volumes with higher recovery than a standard differential centrifugation protocol.

Introduction

Microparticles (MPs, also known as microvesicles) are a class of extracellular vesicles released from various cell types upon activation, stress or apoptosis.¹⁻³ These 100-1000 nm membrane vesicles are present in the circulation of healthy individuals but their levels are altered as a consequence of various pathophysiological processes.⁴⁻⁷ The biological role of MPs is not fully understood, but recent evidence suggest they are key mediators of cell-cell communication, transferring mRNA, microRNA and proteins between cells⁸⁻¹⁰ regulating processes such as antigen presentation¹¹, inflammation¹² and hemostasis¹³.

Platelets are the main source of circulating MPs.¹⁴ MPs are released from platelets upon activation, either through receptor activation (by e.g. thrombin¹⁵), binding of complement proteins¹⁶ or shear stress¹⁷ and are considered both pro-coagulant¹⁸ and pro-inflammatory.^{19,20} Platelet-derived microparticles (PMP) are identified by the expression of platelet surface markers such as CD41, CD42a/b, CD62p and CD63^{21,22}. Elevated levels of platelet-derived MPs (PMPs) are associated with many forms of cardiovascular disease, including peripheral arterial disease²², unstable angina²³ and myocardial infarction.^{22,24,25} Furthermore, PMP levels have been shown to reflect both the myocardium at risk²⁶ and the general level of platelet activation in patients with myocardial infarction.²⁷ Thus, there is both a potential clinical value of using PMPs as biomarkers for various cardiovascular diseases, as well as a biological value in understanding the molecular and physiological function of PMPs. To this end, the ability to quickly and accurately isolate PMPs, both for quantification and for downstream analyses, such as gene- and protein expression analysis, co-culture experiments and other functional studies, is critical.

One concern regarding the analysis of MPs in general is the lack of a consensus protocol for sample preparation.^{28,29} As demonstrated by Lacroix et al., pre-analytical parameters such as centrifugation speed, agitation of tubes or a delay in sample preparation can have a considerable effect on the outcome of the analysis.²⁹ Another concern is the sample volumes required for standard analysis of MPs. In theory, considering the high concentration of MPs in blood, the sample volume required is in the range of a few microliters. However, the centrifugation steps needed to isolate MPs usually require hundreds of microliters. This is a severe limitation, especially when analyzing biobank samples, where there is often restricted access and only very limited amounts of sample can be obtained.

Most researchers use a series of centrifugation steps to prepare plasma for MP analysis.²⁸ Although a consensus protocol is lacking and the variation between labs is considerable, many researchers seem to favor a two-step centrifugation method of 1500xg for 15 minutes followed by 13000xg for 2 minutes.²⁸ However, the second centrifugation step of 13000xg for 2 minutes has been shown to both reduce the MP numbers with about 80%³⁰ and to create artefactual PMPs.²⁹ Moreover, all centrifugation steps will inevitably create a size and density bias in the microparticle population and a method that could isolate MPs with fewer or no centrifugation steps would potentially increase the accuracy and validity of downstream analysis. There is consequently a clear need for a MP isolation method that enables higher recovery, does not negatively affect the MPs integrity and allow limited sample volumes.

Lab-on-a chip techniques have been suggested as a new approach to vesicle isolation due to the small volumes that can be handled and the excellent fluid control. So far, this approach has primarily been aimed at exosomes, vesicles in the 10-100 nm range, and the most common approach is the use of immunoaffinity capture on chip surfaces.³¹⁻³⁵ Immunoaffinity methods have the advantage of being able to selectively capture microparticles by targeting specific antigens expressed on them. However, capturing a variety of vesicles requires a wide range of antibodies and the method is not suitable for recovering vesicles whose surface antigenic profile is unknown. An alternative to a targeted capture through a specific antibody is to attach modified cholesterol to a surface, as presented by Kuhn et al.³⁶ Affinity ligand based vesicle capture

methods, however, still suffer from problems of releasing captured intact vesicles for downstream applications (e.g. co-culture).

Other microfluidic approaches have used filters of different kinds with the inherent problem of clogging the system.^{37,38} He et al. performed an immunoaffinity assay on magnetic nanoparticles and could therefore detain and concentrate the vesicles in the chip prior to lysis and analysis.³⁹ There have also been efforts to perform a size-selective separation of vesicles using deterministic lateral displacement.⁴⁰ Here, intact vesicles could be extracted from the system although no enrichment was achieved.

Acoustofluidics have been used in many different aspects of cell handling, primarily separation but also concentration and trapping.⁴¹⁻⁴³ Acoustic standing waves, typically in the MHz-range, are used to exert size-dependent forces on cells and particles in a gentle and non-contact way.⁴⁴ Objects like bacteria, viruses and vesicles are, however, difficult to affect with acoustic forces due to their minute size. In acoustic trapping, large seed particles have been used to attract and retain bacteria and nanometer-sized beads against flow by secondary acoustic forces between the seed particles and the bacteria or the nanoparticles⁴⁵ and this strategy was recently applied to microparticles as well.^{45,46} This method opens up for the possibility to capture extracellular vesicles using acoustic forces. The main advantages are non-contact capture without any requirements for labeling and the possibility to recover intact vesicles in sample volumes ranging down to 5-10 μL .

In this paper, we present a novel method for rapid non-contact capture of platelet-derived microparticles in minute sample volumes based on a microscale acoustic standing wave technology. We demonstrate that by the use of large seed particles that can easily be retained against flow; acoustic trapping is capable of capturing microparticles on the seed particle cluster from plasma. The system is characterized through fluorescent time-lapse imaging and flow cytometry of the microparticle fraction. Finally, the acoustic technique is compared to a more standardized differential centrifugation protocol using ST-elevation myocardial infarction (STEMI) patient samples from a biobank and healthy controls.

Results and discussion

As a proof-of-principle of the technique and to visualize the trapping of platelet-derived MPs in the cluster of seed particles, cell-free plasma was stained with CD42a-PE and injected into the system under a fluorescence microscope. Images were acquired after injection of 0, 50, 150 and 250 μl of sample and show a clear accumulation of fluorescent material with increased sample volume (Figure 1). The average size of the seed cluster used in this study was of about 1800 particles and it typically covered a volume of about 20 nl ($1 \times 1 \times 0.02 \text{ mm}^3$).




Figure 1. Fluorescent time-lapse images showing acoustic capture of washed CD42-stained microparticles. (A) shows a background image containing only 12 μm plain polystyrene seed particles. (B) was taken after processing 50 μl of microparticle suspension. (C) was taken after a total sample volume of 150 μl and (D) shows the final image after 250 μl sample injection. Microparticle capture can be seen from the increased fluorescent intensity.

To demonstrate that the captured material was actually PMPs, the experiment was repeated with unstained plasma, the cluster was released in PBS, stained and analyzed by flow cytometry. Most of the trapped material ($\sim 90\%$) was contained within the MP gate (Figure 2a) and approximately 20% of the events stained positive for CD42a (Figure 2b). Analysis of the cluster after trapping with a scanning electron microscope (SEM) clearly showed the 12 μm seed particles surrounded by an aggregate of microparticle-sized objects, 300 nm – 1 μm (Figure 2c). Aggregation of the microparticles is believed to be an effect caused by the fixation agent, glutaraldehyde, which previously has been shown to cause platelet aggregation⁴⁷.




Figure 2. (A) Flow cytometry forward scatter (FSC) vs side scatter (SSC) plot showing the microparticle gate. The gate was set using 500 and 800 nm beads, shown in red and blue, respectively. CD42a⁺ microparticles are shown in green. (B) Histogram showing CD42a⁺ events in the microparticle gate (i.e. platelet-derived microparticles). (C) An SEM-image of the seed cluster with captured microparticles. The 12 μm seed particles can be seen clearly and are surrounded by an aggregate of objects 300 nm – 1 μm in size, i.e matching the expected size range of microparticles.

In order to characterize the system and optimize the acoustic trapping, we assessed the effect of altering key parameters on trapping performance. We hypothesized that the high viscosity of plasma would affect trapping negatively, and therefore compared trapping performance in undiluted plasma with plasma that was diluted 1:2 and 1:5 in PBS, using three different sample volumes (10, 50 and 100 μl). All experiments were performed using a flow rate of 10 $\mu\text{l}/\text{min}$. Released clusters were stained for CD42a and the amount of captured microparticles were measured using flow cytometry. Undiluted plasma was shown to have the lowest recovery while plasma diluted 1:5 displayed the highest recovery (Figure 3A). This is most likely due to the fact that diluting the samples changes the viscosity and density of the media surrounding the PMPs, thus yielding a higher acoustic contrast and therefore increasing the recovery. The result also shows that the recovery decreases for increased sample volumes. We believe this is caused by a further dilution of the plasma in the microfluidic system, that is more pronounced for smaller sample volumes due to Taylor dispersion than for larger sample volumes. As the plasma samples are injected through a switch valve upstream of the trapping zone, there will be a total volume of approximately 10–15 μl in the narrow tubing between the injection site and the trapping site. While the sample plug travels through the tubing towards the trapping zone, it will be subjected to a fair amount of dispersion. The dispersion will cause the start and the end of the sample plug to be diluted over a larger volume – leading to a more significant sample dilution for the smaller volumes. Considering the small size of the PMPs and the capacity of the seed particle cluster, it is unlikely that the recovery decrease seen is caused by saturation. However, the total amount of PMP in the sample was comparable between undiluted plasma and plasma diluted 1:2 as the increased recovery counteracted the decrease in PMP concentration caused by the dilution (Figure 3B).




Figure 3. Acoustic capture of microparticles using different plasma concentrations measured using flow cytometry ($n=3$). (A) shows that more diluted plasma leads to higher recovery. A 1:2 dilution was chosen for the following experiment as it had higher recovery than undiluted plasma but about the same amount of extracted microparticles, as seen in (B). The recovery also decreases as the sample volume increases. This is believed to be caused by dispersion-driven dilution in the microfluidic system.

When diluting the plasma, the viscosity and density of the plasma as well as the concentration of the PMPs are changed. To investigate the effect of plasma density and viscosity further we repeated the experiment using fluorescent beads diluted in PBS. Very little effect of dilution on trapping performance with beads, suggesting that this effect is intrinsic to plasma viscosity and density changes and not the PMP concentration (Figure 4). For the remainder of the study, a plasma dilution of 1:2 was used. The intention was to minimize the effect on trapping performance caused by donor dependent variations in plasma viscosity and density.




Figure 4. Acoustic capture of fluorescent, polystyrene nanoparticles, in different concentrations measured using flow cytometry ($n=3$). In (A), the variation in recovery depending on the particle concentration is shown. As in figure 3, a slight decrease in recovery with increased sample volumes can be seen, although much less pronounced. Due to a similar recovery for the different concentrations, the actual amount of extracted particles behaves more as expected (B).

The effect of the sample flow rate on trapping performance was tested by injecting sample with varying flow rate (5, 10 and 25 $\mu\text{l}/\text{min}$) and volume (10, 50 and 100 μl). The released sample clusters were analyzed using flow cytometry to determine the recovery and the amount of PMPs in the sample (Figure 5). No effect of changing the flow rate could be seen for lower sample volumes, although a slower flow rate slightly improved the trapping performance for a 100 μl sample volume. However, the difference was not sufficient to justify the longer run times resulting from the 5 $\mu\text{l}/\text{min}$ flow rate and 10 $\mu\text{l}/\text{min}$ was chosen as the optimal flow rate for the remainder of the study.




Figure 5. Acoustic capture of microparticles in plasma diluted 1:2 using different sample flow rates measured using flow cytometry ($n=3$). For smaller sample volumes the difference in the amount of captured microparticles is small while a lower flow rate is advantageous for larger sample volumes.

In order to show the clinical relevance of the technique, we analyzed plasma PMP levels in patients with ST-elevation myocardial infarction (STEMI) and healthy controls, prepared either with acoustic trapping or a standard differential centrifugation protocol^{3, 29, 48}. Frozen plasma from six STEMI patients and six age and sex matched controls were thawed and prepared for FACS analysis in parallel. The samples were either processed through acoustic trapping of 25 μl of plasma, injected at 10 $\mu\text{l}/\text{min}$ and released in 500 μl of PBS, or through centrifugation at 1500 \times g for 15 minutes, followed by 13000 \times g for 2 minutes. Samples were stained with CD42a-PE and analyzed by FACS. A statistically significant increase in PMPs in STEMI patients compared to healthy controls could be measured using both preparation methods and the results correlated significantly ($r^2=0.38$, $p=0.0328$) (Figure 6). MP recovery was slightly better using acoustic trapping (9.8% compared to 6.3 %, $p=0.045$). The lower general recovery is likely due to the fact that these samples have been stored for a relatively long time at -80 $^{\circ}\text{C}$, which has previously been shown to affect overall microparticle levels.⁴⁹ Acoustic trapping required 1:20 of the sample volume used for standard centrifugation (25 μl versus 500 μl) – a critical point when working with biobank samples of limited volume. While the automated version of the acoustic protocol was completed in 7 minutes the centrifugation protocol was finished after 15 minutes and required manual pipetting steps.




Figure 6. Microparticle extraction from 6 STEMI-patients and 6 healthy controls using differential centrifugation (A) and acoustic trapping (B). Both methods successfully distinguish between the elevated microparticle levels in the STEMI-patients and the lower concentration in the control subjects. One outlier in the STEMI group from the acoustic trapping protocol was identified using Grubb's test and excluded from the analysis. (C) shows the recovery of PMP using either protocol. (D) shows the correlation between trapped PMP for each sample using the two protocols. * indicates $p < 0.05$ by Student's T-test.

Experimental

Theory

The experimental platform is based on seed particle-enabled acoustic trapping in a rectangular glass capillary.^{45, 50} Ultrasonic standing waves are used to create a local acoustic potential in the fluidic channel. The primary acoustic radiation force can be expressed as the gradient of the acoustic potential, consisting of square of the time averages of both the pressure and velocity field.⁴⁴ A particle that is denser or less compressible than the surrounding media will experience a force toward the minimal acoustic potential – corresponding to the pressure node and the velocity antinode. Most plastic particles and cells fall in this category and will move away from the channel walls into the center of the fluidic channel when using a $\lambda/2$ standing wave configuration, see figure 7. While in the pressure node, the forces arising from the higher lateral gradient of the velocity field will keep the particles trapped against a fluid flow.⁵¹ Secondary acoustic forces, arising from sound waves scattered by the trapped particles (seed particles), create attractive forces between the particles in the pressure node, leading to a tightly packed cluster of particles.




Figure 7. A schematic cross-section image of how an acoustic standing wave will collect microparticles using seed particles. In (A), a piezoelectric transducer is used to create a half wavelength standing wave in the fluidic channel. Seed particles are aspirated and trapped in the acoustic potential minimum in the center of the channel. After washing away any excess particles, a microparticle sample can be aspirated into the channel (B). Microparticles will be attracted to the seed particles by secondary acoustic forces. This will result in a cluster of seed particles and captured microparticles in the standing wave. After completing the sample infusion, the flow is reversed to wash the cluster. Finally, the ultrasound is terminated and the cluster can be released for flow cytometry.

The primary radiation force is not strong enough to affect small particles, as it is strongly size dependent ($\sim r^3$), the secondary radiation force, however, scales with the distance between the particles ($\sim d^{-4}$) making it very strong as particles come near each other.⁵² This phenomenon is used in seed trapping where large particles, which are easily handled, are initially trapped and can then trap small particles by the secondary forces.

Experimental setup

A rectangular, borosilicate capillary with inner dimensions of $2 \times 0.2 \text{ mm}^2$ was used as a fluidic channel resulting in a system resonance frequency of around 4 MHz. The capillary is clamped onto a kerfed piezoceramic element and acoustically contacted through a thin film of glycerol.⁵³ The piezoceramic element is surface mounted on a printed circuit board (PCB) to enable actuation through a waveform generator (Figure 8).




Figure 8. A picture of the acoustic trapping system that was used in this study. The piezoelectric transducer is mounted on a PCB with an SMA-connection to a waveform generator. The $2 \times 0.2 \text{ mm}^2$ capillary is clamped to the surface of the transducer and coupled with a thin layer of glycerol. The thin glass walls and small transducer results in a localized standing wave that will trap and hold cells and particles in the center of the capillary above the transducer.

The experimental setup consisted of the acoustic trapping platform, two syringe pumps (neMESYS, Cetoni GmbH, Korbüßen, Germany) and an electrically controlled 4-port switch valve (Cheminert C2, Valco Instruments Company Inc., Houston, TX, USA). The piezoelectric transducer was actuated using a waveform generator (Agilent 33220A, Agilent Technologies Inc., Santa Clara, CA, USA) at 10 V_{pp} . The actuation frequency was determined using a frequency tracking module that automatically finds and holds the optimal resonance frequency in the system, making the system less affected by variations in e.g. plasma constitution and temperature.⁵³ The sample was loaded in a 1 ml disposable syringe in one syringe pump while the other pump handled a 5 ml disposable syringe with phosphate buffered saline (PBS) supplemented with

0.35% bovine serum albumin (BSA). All syringe pumps, the switch valve, the waveform generator and the frequency tracking hardware were controlled through a LabVIEW program.

Work flow for characterization and optimization of acoustic trapping

For optimization and characterization of the system, either plasma from a healthy volunteer or 520 nm fluorescent polystyrene particles (FS03F/5069, Bangs Laboratories, Inc., Fishers, IN, USA) were used. Plasma was obtained by centrifugation of heparinized blood at 1600xg for 15 minutes followed by addition of 50 mM EDTA. PBS buffer was used as a diluent. Polystyrene particles were suspended in PBS supplemented with 0.35% bovine serum albumin (BSA) at a concentration of 50 particles/ μ l.

After activation of the ultrasound, 20 μ l of a suspension containing seeding particles was aspirated from the outlet. Trapped seeding particles were washed with 20 μ l of PBS buffer to remove any excess particles. The average size of the seed cluster used in this study was of about 1800 particles and it typically covered a volume of about 20 nl ($1 \times 1 \times 0.02 \text{ mm}^3$). The valve was switched, connecting the sample syringe to the trapping capillary, and infusion of plasma or polystyrene particle suspension was initiated. After completing the sample infusion, the valve was switched again and the trapping capillary was washed with 40 μ l of PBS buffer. Finally, the ultrasound was deactivated and the cluster flushed into a FACS tube in 500 μ l of PBS buffer for analysis.

Analysis of trapped material was conducted by flow cytometry. CD42a was used as a marker for PMPs throughout the study due to its excellent consistency in PMP staining and a good separation of negative and positive populations. Plasma samples were stained with a phycoerythrin-conjugated anti-CD42a antibody (558819, BD) for 20 minutes protected from light and analyzed on a BD Accuri C6 flow cytometer. The threshold settings were set to 4000 on FSC and 1000 on SSC, and the microparticle gate was set using 500 nm and 800 nm beads (Figure 2a). For PMP quantification, the number of CD42a+ events in the FL-2 channel was determined. Samples containing polystyrene beads were analyzed in the FL-1 channel. The sample volume was set to 200 μ l and a minimum of 10000 events were analyzed in each sample. To calculate the recovery of trapped PMPs, the number of PMPs in the plasma before acoustic trapping was determined. Recovery was calculated by dividing the number of trapped PMPs with the number of PMPs in the plasma before trapping.

Validation of the technique

To validate the system and compare the method with a standard microparticle preparation protocol using differential centrifugation, clinical samples from a biobank was used. Plasma from six patients with ST-elevation myocardial infarction were obtained from the LundHeartGene biobank, Skåne University Hospital, Lund, Sweden. Written informed signed consent had previously been given. STEMI diagnosis was based on patient history and ECG-criteria. Plasma had been prepared as described above and stored at -80°C . As controls, six healthy, age and sex matched volunteers were recruited and plasma was obtained and stored as described above. Before analysis, samples were thawed at room temperature. For acoustic trapping, a 25 μ l aliquot was diluted 1:2 with PBS and run in the system at 10 μ l/min, washed and released in 500 μ l PBS with 0.35% BSA. In contrast to the method described above, samples were aspirated from the end of the capillary rather than injected through a syringe. This method enabled the analysis of small sample volumes that would have been problematic to load in a syringe. However, since the trapping site is roughly centered on the capillary (see Figure 8) there is a volume of about 10-15 μ l at the end of the capillary from which no PMPs will be captured. The 25 μ l that was withdrawn then correlates to injecting 10 μ l as was done with the other samples during characterization. The volume preceding the trapping site can be minimized by utilizing a shorter capillary.

For comparison, a well established differential centrifugation protocol was used.^{28,48} The protocol consists of two centrifugation steps, 1600* g for 15 minutes followed by 13000* g for 2 minutes. The decision to use this protocol as a reference was based on several criteria. First, it is one of the most commonly used protocols (see e.g. the summary by Yuana et al.⁵⁴). Second, seeing as platelet contamination is considered one of the major pre-analytical problems in processing plasma for MP measurement⁵⁴, the use of a second centrifugation step of 13000* g , which has previously been shown to eliminate 99% of platelets from platelet poor plasma⁵⁵, was considered important for validity of MP quantification after sample preparation. Third, the use of MP isolation with high speed centrifugation (17000-20000* g) as used by many researchers (see e.g. Berckmans et al.⁵⁶ and van der Zee et al.²²) has been shown to result in a significant loss of MPs as well as an alteration in MP integrity⁵⁷, and was therefore disregarded in this study. 500 μ l of platelet poor plasma from patients or controls was subjected to the centrifugation protocol. The number and recovery of CD42a+ MPs obtained with acoustic trapping and differential centrifugation was determined by flow cytometry as described above.

SEM analysis

A sample run was performed according to the processing flow described in the sample processing subsection using 100 μ l of cell-free plasma. After the final rinse of the cluster, a 2.5% glutaraldehyde solution was withdrawn in the capillary to fix the PMPs. After a 5 min incubation, the fixing solution was removed by a PBS wash for 10 minutes. Microparticles were dehydrated using an ethanol dilution series with 10 minutes each at 30%, 50%, 75%, 95% and 99.7%. Finally, the cluster was released onto a conductive carbon adhesive film and analyzed at 100 mbar using a Hitachi SU1510 Variable Pressure SEM.

Statistical analysis

All experiments were done in triplicates and statistical analysis was carried out in GraphPad Prism v 6.0c (GraphPad, La Jolla, CA, USA). Data represent the mean \pm SEM and differences between groups were analyzed by Student's t-test.

Correlation was analyzed with linear regression. Statistical significance was considered when $p < 0.05$. Outlier detection was performed with the Grubb's test with a significance level of 0.05.

Future developments

The possibility to release intact microparticles enables a wide variation of analysis methods, e.g. flow cytometry, qRT-PCR, mass spectrometry, western blotting, as well as functional assays and co-culture experiments. The miniaturized flow-through format also enables integration with other miniaturized techniques, e.g. integrating a plasmapheresis system upstream⁵⁸ to extract microparticles directly from whole blood. It would also be possible to develop a system with multiple acoustic traps where one trap would hold a cell population that upon stimulation releases vesicles that subsequently are captured by a second acoustic trap and then further analyzed downstream. This would enable a targeted analysis of vesicles from a specific cell group in a well-defined microenvironment.

Conclusion

We have shown that acoustic trapping can be used for capture of platelet-derived microparticles from human plasma samples. The technique offers a quick and automated setup for isolating microparticles from small sample volumes with higher recovery than a standard differential centrifugation protocol.

Acknowledgements

This work was funded by Knut and Alice Wallenberg Foundation and the Swedish Foundation for Strategic Research. The authors also would like to thank Martin Bengtsson for the help with the SEM analysis, Siv Svensson for sample collection and all the volunteers who helped us by providing blood samples.

References

1. E. Biró, J. W. N. Akkerman, F. J. Hoek, G. Gorter, L. M. Pronk, a. Sturk and R. Nieuwland, *Journal of thrombosis and haemostasis : JTH*, 2005, 3, 2754-2763.
2. A.-C. Vion, B. Ramkhalawon, X. Loyer, G. Chironi, C. Devue, G. Loirand, A. Tedgui, S. Lehoux and C. M. Boulanger, *Circulation research*, 2013, 112, 1323-1333.
3. F. Dignat-George and C. M. Boulanger, *Arteriosclerosis, thrombosis, and vascular biology*, 2011, 31, 27-33.
4. S. Mezouar, D. Mege, R. Darbousset, D. Farge, P. Debourdeau, F. Dignat-George, L. Panicot-Dubois and C. Dubois, *Seminars in oncology*, 2014, 41, 346-358.
5. J.-M. Sinning, J. Losch, K. Walenta, M. Böhm, G. Nickenig and N. Werner, *European heart journal*, 2011, 32, 2034-2041.
6. T. Nozaki, S. Sugiyama, K. Sugamura, K. Ohba, Y. Matsuzawa, M. Konishi, J. Matsubara, E. Akiyama, H. Sumida, K. Matsui, H. Jimouchi and H. Ogawa, *European journal of heart failure*, 2010, 12, 1223-1228.
7. T. Helbing, C. Olivier, C. Bode, M. Moser and P. Diehl, *World journal of cardiology*, 2014, 6, 1135-1139.
8. M. Mack, A. Kleinschmidt, H. Bruhl, C. Klier, P. J. Nelson, J. Cihak, J. Plachy, M. Stangassinger, V. Erfle and D. Schlondorff, *Nature medicine*, 2000, 6, 769-775.
9. H. Valadi, K. Ekstrom, A. Bossios, M. Sjostrand, J. J. Lee and J. O. Lotvall, *Nature cell biology*, 2007, 9, 654-659.
10. O. Gidlof, M. van der Brug, J. Ohman, P. Gilje, B. Olde, C. Wahlestedt and D. Erlinge, *Blood*, 2013, 121, 3908-3917, S3901-3926.
11. M. Mittelbrunn, C. Gutierrez-Vazquez, C. Villarroya-Beltri, S. Gonzalez, F. Sanchez-Cabo, M. A. Gonzalez, A. Bernad and F. Sanchez-Madrid, *Nature communications*, 2011, 2, 282.
12. A. Zernecke, K. Bidzhekov, H. Noels, E. Shagdarsuren, L. Gan, B. Denecke, M. Hristov, T. Koppel, M. N. Jahantigh, E. Lutgens, S. Wang, E. N. Olson, A. Schober and C. Weber, *Science signaling*, 2009, 2, ra81.
13. P. L. Gross, B. C. Furie, G. Merrill-Skoloff, J. Chou and B. Furie, *Journal of leukocyte biology*, 2005, 78, 1318-1326.
14. S. F. Mause and C. Weber, *Circulation research*, 2010, 107, 1047-1057.
15. A. P. Bode and D. H. Hickerson, *Platelets*, 2000, 11, 259-271.
16. P. J. Sims, E. M. Faioni, T. Wiedmer and S. J. Shattil, *The Journal of biological chemistry*, 1988, 263, 18205-18212.
17. Y. Miyazaki, S. Nomura, T. Miyake, H. Kagawa, C. Kitada, H. Taniguchi, Y. Komiyama, Y. Fujimura, Y. Ikeda and S. Fukuhara, *Blood*, 1996, 88, 3456-3464.
18. A. P. Owens, 3rd and N. Mackman, *Circ Res*, 2011, 108, 1284-1297.
19. E. Boilard, P. A. Nigrovic and K. Larabee, *Science*, 2010, 45.
20. G. T. Brown and T. M. McIntyre, *Journal of immunology (Baltimore, Md. : 1950)*, 2011, 186, 5489-5496.
21. F. Mobarrez, J. Antovic, N. Egberg, M. Hansson, G. Jörneskog, K. Hultenby and H. Wallén, *Thrombosis research*, 2010, 125, e110-116.
22. P. M. van der Zee, E. Biró, Y. Ko, R. J. de Winter, C. E. Hack, A. Sturk and R. Nieuwland, *Clinical chemistry*, 2006, 52, 657-664.
23. C. Vidal, C. Spaulding and F. Picard, *THROMBOSIS AND ...*, 2001, 784-790.
24. O. Morel, P. Ohlmann, E. Epailly, B. Bakouboula, F. Zobairi, L. Jesel, N. Meyer, M.-P. Chenard, J.-M. Freyssinet, P. Bareiss, J.-P. Mazzucotelli and F. Toti, *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*, 2008, 27, 38-45.
25. A. E. Michelsen, E. Brodin, F. Brosstad and J.-B. Hansen, *Scandinavian journal of clinical and laboratory investigation*, 2008, 68, 386-392.
26. C. Jung, P. Sörensson, N. Saleh, H. Arheden, L. Rydén and J. Pernow, *Atherosclerosis*, 2012, 221, 226-231.
27. E. Stepien, E. Stankiewicz, J. Zalewski, J. Godlewski, K. Zmudka and I. Wybrańska, *Archives of medical research*, 2012, 43, 31-35.
28. W. Jy and L. L. Horstman, *Journal of Thrombosis ...*, 2004, 1842-1843.
29. R. Lacroix, C. Judicone, P. Poncelet, S. Robert, L. Arnaud, J. Sampol and F. Dignat-George, *Journal of thrombosis and haemostasis : JTH*, 2012, 10, 437-446.
30. L. L. Horstman, W. Jy and J. J. Jimenez, *The Keio journal of ...*, 2004, 210-230.

31. B. A. Ashcroft, J. de Sonnevile, Y. Yuana, S. Osanto, R. Bertina, M. E. Kuil and T. H. Oosterkamp, *Biomedical microdevices*, 2012, 14, 641-649.
32. C. Chen, B.-R. Lin, H.-K. Wang, S.-T. Fan, M.-Y. Hsu and C.-M. Cheng, *Microfluidics and Nanofluidics*, 2014, 16, 849-856.
33. C. Chen, J. Skog, C. H. Hsu, R. T. Lessard, L. Balaj, T. Wurdinger, B. S. Carter, X. O. Breakefield, M. Toner and D. Irimia, *Lab Chip*, 2010, 10, 505-511.
34. H. Shao, J. Chung, L. Balaj, A. Charest, D. D. Bigner, B. S. Carter, F. H. Hochberg, X. O. Breakefield, R. Weissleder and H. Lee, *Nature medicine*, 2012, 18, 1835-1840.
35. S. S. Kanwar, C. J. Dunlay, D. M. Simeone and S. Nagrath, *Lab Chip*, 2014, 14, 1891-1900.
36. P. Kuhn, K. Eyer, T. Robinson, F. I. Schmidt, J. Mercer and P. S. Dittrich, *Integrative biology : quantitative biosciences from nano to macro*, 2012, 4, 1550-1555.
37. R. T. Davies, J. Kim, S. C. Jang, E. J. Choi, Y. S. Gho and J. Park, *Lab Chip*, 2012, 12, 5202-5210.
38. Z. Wang, H. J. Wu, D. Fine, J. Schmulen, Y. Hu, B. Godin, J. X. Zhang and X. Liu, *Lab Chip*, 2013, 13, 2879-2882.
39. M. He, J. Crow, M. Roth, Y. Zeng and A. K. Godwin, *Lab Chip*, 2014, 14, 3773-3780.
40. S. M. Santana, M. A. Antonyak, R. A. Cerione and B. J. Kirby, *Biomedical microdevices*, 2014, 16, 869-877.
41. A. Lenshof, C. Magnusson and T. Laurell, *Lab on a chip*, 2012, 12, 1210-1223.
42. M. Nordin and T. Laurell, *Lab on a Chip*, 2012, 12, 4610-4616.
43. M. Evander and J. Nilsson, *Lab Chip*, 2012, 12, 4667-4676.
44. H. Bruus, *Lab on a chip*, 2012, 12, 1014-1021.
45. B. Hammarstrom, T. Laurell and J. Nilsson, *Lab on a chip*, 2012, 12, 4296-4304.
46. M. Evander, O. Gidlöf, D. Erlinge and T. Laurell, presented in part at the Micro Total Analysis Systems 2014, San Antonio, TX, USA, 2014.
47. J. A. Zeller, R. E. Dayhoff, K. Eurenus, W. Russell and R. S. Ledley, *Clinical and laboratory haematology*, 1984, 6, 145-155.
48. J. M. Freyssinet, *J Thromb Haemost*, 2003, 1, 1655-1662.
49. E. Dey-Hazra, B. Hertel, T. Kirsch, A. Woywodt, S. Lovric, H. Haller, M. Haubitz and U. Erdbruegger, *Vascular health and risk management*, 2010, 6, 1125-1133.
50. B. Hammarstrom, M. Evander, H. Barbeau, M. Bruzelius, J. Larsson, T. Laurell and J. Nilsson, *Lab on a chip*, 2010, 10, 2251-2257.
51. P. Glynne-Jones, C. E. M. Demore, Y. Congwei, Q. Yongqiang, S. Cochran and M. Hill, *Ultrasonics, Ferroelectrics and Frequency Control, IEEE Transactions on*, 2012, 59, 1258-1266.
52. M. Groschl, *Acustica*, 1998, 84, 432-447.
53. B. Hammarstrom, M. Evander, J. Wahlstrom and J. Nilsson, *Lab on a Chip*, 2014, 14, 1005-1013.
54. Y. Yuana, R. M. Bertina and S. Osanto, *Thrombosis and haemostasis*, 2011, 105, 396-408.
55. W. L. Chandler, *Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis*, 2013, 24, 125-132.
56. R. J. Berckmans, R. Nieuwland, A. N. Boing, F. P. Romijn, C. E. Hack and A. Sturk, *Thrombosis and haemostasis*, 2001, 85, 639-646.
57. S. Robert, P. Poncelet, R. Lacroix, L. Arnaud, L. Giraud, A. Hauchard, J. Sampol and F. Dignat-George, *J Thromb Haemost*, 2009, 7, 190-197.
58. A. Lenshof, A. Ahmad-Tajudin, K. Järås, A.-M. Swärd-Nilsson, L. Åberg, G. Marko-Varga, J. Malm, H. Lilja and T. Laurell, *Analytical Chemistry*, 2009, 81, 6030-6037.

Table of contents entry

An acoustic non-contact method for extracting platelet-derived microparticles from small plasma volumes is presented. The method has higher recovery and can handle smaller sample volumes than the conventional differential centrifugation method. It is optimal for the analysis of precious biobank samples with limited volume.

